PROTEIN C Property

storage temp. 

-20°C

solubility 

H₂O: 1 mg/mL

form 

lyophilized powder

biological source

rabbit

Water Solubility 

H2O: 1mg/mL

Safety

Hazard Codes 

B

Risk Statements 

36/37

Safety Statements 

36/37-36-26

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

PROTEIN C Chemical Properties,Usage,Production

Description

Drotrecogin alfa was introduced in the US as a new intravenous treatment for the reduction of mortality in adult patients with severe sepsis associated with acute organ dysfunction. Drotrecogin aifa is the first recombinant activated protein C expressed in human kidney 293 cells. Activated protein C₁ an endogenous serine protease, acts as an antithrombotic via inhibition of factor Va and Vllla, promotes fibrinolysis via inactivation of plasminogen-activator inhibitor-1 and exerts an anti-inflammatory effect by inhibiting the production of inflammatory cytokines (tumor necrosis factor-alpha, interieukin-1 and 6) by monocytes. It was shown that the majority of patients with sepsis have reduced levels of activated protein C. In a baboon model of lethal E. coli sepsis, administration of activated protein C reduced mortality. In a phase III clinical trial, intravenous infusion of drotrecogin alfa at a dose of 24 μg/kg/h over 96 h significantly reduced the risk of death compared with placebo in patients with severe sepsis. However, an increased risk of serious bleeding has been associated with the administration of the drug.

Originator

Lilly (US)

Uses

Protein C from human plasma has been used for pre-treatment of endothelial cells prior to antibody-inhibition assay. It has also been used in activated protein C (APC) assay to determine its inhibitory effect on copper.

brand name

Xigris

General Description

Protein C from human plasma is encoded by the gene PROC. In human chromosome, the gene is localised on chromosome 2q14. Activated protein C (APC) cleaves protease activated receptor 1 (PAR1) resulting in cytoprotective and anti-inflammatory effects. Clinical trials with APC implicates its use in treating severe early onset preeclampsia in pregnant women and prolongs pregnancy and helps in perinatal outcomes.

Biochem/physiol Actions

Adenomatous Polyposis Coli (APC) has a key role in the proteasome-mediated degradation of β-catenin. APC mutations cause accumulation of β-catenin in the nucleus leading to activation of LEF-1 and/or TCF, and the induction of target genes such as the oncogene c-myc. It is involved in regulation of mitotic chromosome separation and stability.